Novo Nordisk Slashes US List Prices Of Several Insulin Products By Up To 75%

RTTNews | 1341 hari yang lalu
Novo Nordisk Slashes US List Prices Of Several Insulin Products By Up To 75%

(RTTNews) - Healthcare company Novo Nordisk Inc. (NVO) announced Tuesday it is lowering the U.S. list prices of several pre-filled insulin pens and vials by up to 75% for people living with type 1 and type 2 diabetes.

The products include both pre-filled pens and vials of basal (long-acting), bolus (short-acting) and pre-mix insulins, specifically Levemir, Novolin, NovoLog and NovoLog Mix 70/30.

Novo Nordisk is also reducing the list price of unbranded biologics to match the lowered price of each respective branded insulin. These changes will go into effect on January 1, 2024.

Novo Nordisk currently provides co-pay support for a number of insulin products, meaning eligible patients can pay $25 to $35 for their insulin.

Novo Nordisk recognizes that some patients find it difficult to pay for healthcare, including insulin. As such, the Company remains committed to reducing the burden of out-of-pocket costs, helping transform the complex pricing system, and fostering better pricing predictability.

Novo Nordisk continually reviews and revises its offerings as well as works with diverse stakeholders to create solutions for differing patient needs.

baca selengkapnya
Novo Nordisk Stock Climbs On Higher Q1 Results; Cuts FY25 Outlook

Novo Nordisk Stock Climbs On Higher Q1 Results; Cuts FY25 Outlook

Shares of Novo Nordisk A/S were gaining around 6 percent in Denmark as well as around 7 percent in the pre-market activity on the NYSE, after the Danish drug major reported Wednesday higher profit and sales in its first quarter, mainly reflecting improved results of its blockbuster weight loss drug Wegovy. Meanwhile, the company trimmed fiscal 2025 outlook for sales and operating profit growth...
RTTNews | 556 hari yang lalu
Novo Nordisk Plans $4.1 Bln NC Facility To Boost Obesity Drug Supply

Novo Nordisk Plans $4.1 Bln NC Facility To Boost Obesity Drug Supply

Danish drug maker Novo Nordisk announced its plans to invest $4.1 billion or about 27 billion Danish kroner to build a new manufacturing plant in Clayton, North Carolina with a view to expanding its manufacturing capacity in the United States. In the new plant, the company plans to produce current and future injectable treatments for people with obesity and other serious chronic diseases.
RTTNews | 872 hari yang lalu
U.S. Dollar Advances Amid Middle East Tensions, Tech Sector Slide

U.S. Dollar Advances Amid Middle East Tensions, Tech Sector Slide

The U.S. Dollar value moved higher on Friday after the U.S. and Iran adopted a tougher stance against any agreement and trounced expectations for a deal to end their conflict and reopen the Strait of Hormuz. In addition, the slide in the IT stocks due to Nvidia crisis weighed on the equity markets.
RTTNews | 17 jam 15 menit yang lalu
Swiss Market Ends On Weak Note

Swiss Market Ends On Weak Note

The Switzerland stock market ended modestly lower on Friday after languishing in negative territory throughout the trading session, as traders seemed reluctant to build up fresh positions amid a lack of positive news.
RTTNews | 20 jam 40 menit yang lalu
European Stocks End On Mixed Note After Cautious Session

European Stocks End On Mixed Note After Cautious Session

European stocks turned in a mixed performance on Friday as investors made cautious moves amid uncertainty over the outlook for the AI trade and possibility of a rate hike by the Federal Reserve in December. Optimism about corporate earnings aided sentiment a bit.
RTTNews | 21 jam 12 menit yang lalu